Protara Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Protara Therapeutics, Inc. (TARA) reported Increase Decrease In Operating Lease Liability of -$610.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- Protara Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$308.00K.
- Protara Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$302.00K.
- Protara Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$297.00K.
- Protara Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$292.00K.
- Protara Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$1.12M.
- Protara Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$984.00K.
- Protara Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$917.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$308.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$610.00K 10-Q · filed 2026-08-11 | -$907.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.20M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$302.00K 10-Q · filed 2026-05-13 | -$599.00K derived: sum of 2 quarters · filed 2026-05-13 | -$891.00K derived: sum of 3 quarters · filed 2026-05-13 | -$1.17M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$297.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$589.00K derived: sum of 2 quarters · filed 2026-03-10 | -$868.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.12M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$292.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$571.00K derived: sum of 2 quarters · filed 2026-08-11 | -$827.00K 10-Q · filed 2025-11-10 | -$1.08M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$279.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$535.00K 10-Q · filed 2026-08-11 | -$788.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.04M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$256.00K 10-Q · filed 2026-05-13 | -$509.00K derived: sum of 2 quarters · filed 2026-05-13 | -$757.00K derived: sum of 3 quarters · filed 2026-05-13 | -$1.00M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$253.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$501.00K derived: sum of 2 quarters · filed 2026-03-10 | -$744.00K derived: sum of 3 quarters · filed 2026-03-10 | -$984.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | -$248.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$491.00K derived: sum of 2 quarters · filed 2025-11-10 | -$731.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | -$243.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$483.00K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | -$240.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$917.00K 10-K · filed 2025-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |